NASDAQ:BIIB Biogen Q3 2026 Earnings Report $225.01 -0.87 (-0.39%) As of 03:13 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biogen EPS ResultsActual EPSN/AConsensus EPS $2.03Beat/MissN/AOne Year Ago EPSN/ABiogen Revenue ResultsActual RevenueN/AExpected Revenue$2.64 billionBeat/MissN/AYoY Revenue GrowthN/ABiogen Announcement DetailsQuarterQ3 2026Date10/28/2026TimeBefore Market OpensConference Call DateWednesday, October 28, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Biogen Earnings Headlines1 Profitable Stock Worth Investigating and 2 We IgnoreOctober 1 at 9:50 AM | finance.yahoo.comHLS Therapeutics Announces Board of Directors ChangesOctober 1 at 9:50 AM | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 1 at 1:00 AM | Banyan Hill Publishing (Ad)Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?September 28 at 3:02 PM | finance.yahoo.comBiogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics PackSeptember 25, 2026 | finance.yahoo.comHow Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease DataSeptember 23, 2026 | finance.yahoo.comSee More Biogen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biogen and other key companies, straight to your email. Email Address About BiogenBiogen (NASDAQ:BIIB) is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders. Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia. The company also partnered with Eisai on Leqembi (lecanemab), an Alzheimer’s disease treatment, and has participated in the development and commercialization of biosimilars through its collaboration with Samsung Bioepis. Founded in 1978, Biogen is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world. The company’s operations include research and development, regulatory support, manufacturing and commercial activities across North America, Europe and other international regions. Biogen is led by Chief Executive Officer Christopher A. Viehbacher.View Biogen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
